Status:
SUSPENDED
Evaluation of the Safety of Relaxin in Preeclampsia
Lead Sponsor:
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Conditions:
Pre-Eclampsia
Eligibility:
FEMALE
18-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
Detailed Description
The effects of relaxin may be beneficial in the treatment of women with preeclampsia. This study will preliminarily evaluate the maternal, fetal and neonatal safety and tolerability of an IV infusion ...
Eligibility Criteria
Inclusion
- Diagnosis of preeclampsia
- Hospital admission for expectant management
Exclusion
- Eclampsia or history of seizures
- Vaginal bleeding
- Multifetal gestation
- Requirement for immediate delivery
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00333307
Start Date
October 1 2006
Last Update
March 16 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
2
University of Cincinnati
Cincinnati, Ohio, United States, 45267